AKBA 8-K 2026-10-14

Akebia Therapeutics, Inc. (AKBA) 8-K dated 2026-10-14 — accession 0001517022-26-000071. This URL is the filing, not the AKBA hub.

Akebia Therapeutics, Inc. (AKBA) is a drug manufacturers - specialty & generic company listed on US.

Akebia Therapeutics, Inc. filed a 8-K on 2026-10-14. Accession 0001517022-26-000071.

Cached items: 5.02. EDGAR remains the official archive; Lician keeps this accession as its own indexable page so Google can recrawl the form, not a ticker dump.

Latest reported AKBA revenue for 2025-12-31 was $236.2M. Net income was -$5.3M. Revenue was up 47.5% from 2024-12-31 to 2025-12-31. AKBA currently screens at market cap $260.1M.

Not investment advice. The AKBA SEC hub lists recent forms. The stock page is the research view.